The company said it will use the proceeds of the financing to continue the development of a technology platform and associated applications.
The genomic sequencing firm will use the financing to support growth in both the research and clinical NGS market.
The company plans to use the proceeds to support research collaborations and to expand its commercial team.
The firm said it would use any net proceeds for R&D, working capital, and to potentially acquire other technologies or businesses.
The company said it will use the funds to complete and launch Mastermind, its flagship product for analyzing and interpreting variant data.
The company hopes to sequence about 60,000 whole genomes, and genotype 100,000 individuals to accelerate clinically relevant discoveries.
The company said it will use the proceeds to further develop its core software platform, and to hire additional programmers and bioinformaticians.
The company plans to use the funds to build up a Dublin-based genomic research and development program based on the model of Iceland's Decode Genetics.
The Harvard spinout plans to use the proceeds to expand its service offerings, and to seek partnerships with researchers and hospitals around the world.
ReadCoor is currently using its its technology to map neural circuits in the brain and has projects in the pipeline related to oncology and infectious disease.
In Science this week: genetic analysis of pollutant-tolerant fish, and more.
Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.
New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.
NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.